首页 › 基金 › Vestal Point Capital, LP › ZBIO
Vestal Point Capital, LP 对 ZBIO 的持仓历史
ZENAS BIOPHARMA INC · 医疗保健
Vestal Point Capital, LP 在 Q3 2026 的 13F 申报中披露持有 ZBIO(ZENAS BIOPHARMA INC)395,000 股,市值约 US$10.7M,约占其申报组合的 0.28%,在其申报持仓中市值排名第 37 位。 Vestal Point Capital, LP 最近 3 个申报季度中有 3 个季度披露了 ZBIO 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Vestal Point Capital, LP 对 ZBIO 的持仓演变
Vestal Point Capital, LP 于 Q1 2026 首次披露 ZBIO 持仓:200,000 股(约 US$3.9M)。 该持仓在 Q3 2026 达到峰值 395,000 股,市值约 US$10.7M。 在 3 次申报中,Vestal Point Capital, LP 2 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 395,000 股、市值约 US$10.7M,环比增持 30,000 股。。 持仓曾出现大幅变动:Q2 2026 增持约 82% (随后一个季度股价上涨 6%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 200.00K | $3.91M | 新进 |
| Q2 2026 | 365.00K | $9.26M | 增持 |
| Q3 2026 | 395.00K | $10.65M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ZBIO 与 13F 数据
ZBIO(ZENAS BIOPHARMA INC)属于医疗保健行业。我们追踪的基金中还有 59 只申报持有 ZBIO,申报仓位最大的包括:SR ONE CAPITAL MANAGEMENT, LP (US$135.9M), NEA Management Company, LLC (US$108.5M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$85.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ZBIO 的基金
- SR ONE CAPITAL MANAGEMENT, LP 5.04M 股 · $135.87M · Q3 2026
- NEA Management Company, LLC 4.02M 股 · $108.51M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M 股 · $85.74M · Q3 2026
- Enavate Sciences GP, LLC 2.92M 股 · $78.73M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 2.39M 股 · $64.41M · Q3 2026
- Fairmount Funds Management LLC 2.37M 股 · $63.96M · Q3 2026
- NVP Associates, LLC 1.84M 股 · $49.58M · Q3 2026
- Context Capital Management, LLC 31.05M 股 · $39.70M · Q3 2026
- Graham Capital Management, L.P. 21.25M 股 · $27.32M · Q3 2026
- EcoR1 Capital, LLC 789.50K 股 · $21.29M · Q3 2026
- ArrowMark Colorado Holdings LLC 527.98K 股 · $14.24M · Q3 2026
- Rock Springs Capital Management LP 502.08K 股 · $13.54M · Q3 2026
更多关于 Vestal Point Capital, LP
常见问题
How long has Vestal Point Capital, LP held ZBIO?
Vestal Point Capital, LP has disclosed ZBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Vestal Point Capital, LP's current position in ZBIO?
As of Q3 2026, Vestal Point Capital, LP holds 395.00K shares of ZBIO (ZENAS BIOPHARMA INC), valued at $10.65M, representing 0.28% of its reported portfolio and ranking #37.
Has Vestal Point Capital, LP been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP increased its position in ZBIO. The position peaked in Q3 2026 at 395.00K shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.